𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial

✍ Scribed by Raju Kapoor; Julian Furby; Thomas Hayton; Kenneth J Smith; Daniel R Altmann; Robert Brenner; Jeremy Chataway; Richard AC Hughes; David H Miller

Book ID
114409538
Publisher
The Lancet
Year
2010
Tongue
English
Weight
251 KB
Volume
9
Category
Article
ISSN
1474-4465

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Glatiramer acetate in primary progressiv
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
✍ Jerry S. Wolinsky; Ponnada A. Narayana; Paul O'Connor; Patricia K. Coyle; Corey πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 349 KB πŸ‘ 2 views

## Abstract ## Objective To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis. ## Methods A total of 943 patients with primary progressive multiple sclerosis were randomized to GA or placebo (PBO) in this 3‐year, double‐blind tri

Rituximab in patients with primary progr
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 158 KB πŸ‘ 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro